Fludarabine Phosphete and Melphalan - An Immunosuppressive Reduced Intensity Conditioning (RIC) Regimen for AUogeneic Stem Cell Transplantation in Patients with a Range of Hematological Malignancies

摘要

Twelve patients with a variety of hematological malignancies rapidly achieved donor engraftment following RIC with fludarabine phosphate and melphalan. Four of the 10 patients whose response was assessed at 3 months showed an improvement in disease remission status, and 6 remained in complete remission (CR). At a median of 12 months follow-up (range 0-24), all 10 of these patients (83% of total) are alive and without evidence of relapse. Patients experienced a low incidence of severe infection up to day +100 (2 patients; 17%). Graft-versus-host disease (GVHD) was the main cause of treatment-related morbidity and mortality, and 2 patients (17%) died of grade 4 acute GVHD (aGVHD). This remains the main area of concern in some allogeneic RIC transplantation regimens.